Co-exhibition in 2017 New Cardiovascular Horizons (NCVH) Annual Conference

201705105

Co-exhibition in 2017 New Cardiovascular Horizons (NCVH) Annual Conference

May 10, 2017—BrosMed will co-exhibit her PTCA and PTA products family with strategic partner US Endovascular in upcoming the 2017 New Cardiovascular Horizons (NCVH) Annual Conference in New Orleans, May 31-June 02. NCVH is the international, multispecialty conference showcasing excellence in vascular medicine and intervention.

About New Cardiovascular Horizons
NCVH is an educational nonprofit foundation focused on multidisciplinary accredited conferences to advance the field of cardiovascular care using endovascular technologies, pharmacotherapy treatments, peripheral interventions and amputation prevention techniques. With a goal to empower healthcare providers with knowledge of head-to-toe vascular treatments, NCVH strives to promote interdisciplinary teamwork and collaboration to address the continuum of patient care.201705101

 

About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.

BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.

We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.

BrosMed Medical product portfolio consist of, Artimes™ PTCA, Apollo™ NC PTCA, Atropos™ 0.035 PTA, Minerva™ 0.018 PTA, Polux™ 0.014 PTA, Hermes™ NC 0.035 PTA, Achilles™ NC 0.018 PTA, Castor™ NC 0.014 PTA, Conger™ Hydrophilic coated wire and Freepath™ Catheter Sheath Introducer. BrosMed Medical is supplying safe, effective and hi-tech medical devices in 30 countries.201705102

 

 

About US Endovascular (USE)
US Endovascular (USE) is engaged in the procurement, licensing & distribution of medical device products used in peripheral endovascular and coronary procedures. The fundamental premise is to obtain next-generation, clinically-relevant products from manufacturers and market directly to the end user/ economic buyer. This approach eliminates all unnecessary layers, significantly reducing cost.

USE product portfolio includes: next-generation peripheral arterial laser technology (pending FDA 510k approval); next-generation PTA and PTCA balloon technology; peripheral guide wires. These product segments are used in greater than 95% of peripheral and endovascular and coronary procedures.201705103